Cargando…
Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy
BACKGROUND: Methyl-aminolevulinate photodynamic therapy (MAL-PDT) is an excellent option for the treatment of basal cell carcinoma (BCC). However, up to 25% of cases are resistant to this treatment modality. OBJECTIVE: The aim of this study was to identify potential biomarkers of BCC response to MAL...
Autores principales: | Gracia-Cazaña, Tamara, Mascaraque, Marta, Lucena, Silvia Rocío, Vera-Álvarez, Jesús, González, Salvador, Juarranz, Ángeles, Gilaberte, Yolanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481917/ https://www.ncbi.nlm.nih.gov/pubmed/31017970 http://dx.doi.org/10.1371/journal.pone.0215537 |
Ejemplares similares
-
Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells
por: Mascaraque, Marta, et al.
Publicado: (2020) -
Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer
por: Lucena, Silvia Rocío, et al.
Publicado: (2015) -
Mitotic Catastrophe Induced in HeLa Tumor Cells by Photodynamic Therapy with Methyl-aminolevulinate
por: Mascaraque, Marta, et al.
Publicado: (2019) -
Characterisation of resistance mechanisms developed by basal cell carcinoma cells in response to repeated cycles of Photodynamic Therapy
por: Lucena, Silvia Rocio, et al.
Publicado: (2019) -
Tumor microenvironment in non-melanoma skin cancer resistance to photodynamic therapy
por: Cerro, Paulina A., et al.
Publicado: (2022)